RBC Capital Believes Alexion Pharmaceuticals (NASDAQ: ALXN) Won’t Stop Here

By Austin Angelo

Alexion Pharmaceuticals (NASDAQ: ALXN) received a Buy rating and a $161 price target from RBC Capital analyst Simos Simeonidis today. The company’s shares closed yesterday at $144.61, close to its 52-week high of $149.34.

Simeonidis has an average return of 11.7% when recommending Alexion Pharmaceuticals.

According to TipRanks.com, Simeonidis is ranked #4550 out of 4642 analysts.

Currently, the analyst consensus on Alexion Pharmaceuticals is Strong Buy and the average price target is $162.31, representing a 12.2% upside.

In a report issued on September 5, J.P. Morgan also upgraded the stock to Buy with a $175 price target.

Based on Alexion Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $893 million and quarterly net profit of $165 million. In comparison, last year the company earned revenue of $737 million and had a net profit of $115 million.

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.